1939
DOI: 10.1172/jci101064
|View full text |Cite
|
Sign up to set email alerts
|

The Formation of Methemoglobin and Sulfhemoglobin During Sulfanilamide Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
6
0

Year Published

1939
1939
1965
1965

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 22 publications
(6 citation statements)
references
References 16 publications
0
6
0
Order By: Relevance
“…Clinical methemoglobemia has been noted to depend upon the concentration of sulfanilamide in the blood, and to reach a peak several hours after the sulfanilamide concentration of the blood had reached its peak (5). The methemoglobinemia of patients was also found to depend slightly upon the concentration of circulating hemoglobin.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Clinical methemoglobemia has been noted to depend upon the concentration of sulfanilamide in the blood, and to reach a peak several hours after the sulfanilamide concentration of the blood had reached its peak (5). The methemoglobinemia of patients was also found to depend slightly upon the concentration of circulating hemoglobin.…”
Section: Discussionmentioning
confidence: 99%
“…
Methemoglobin formation generally occurs during sulfanilamide therapy in humans (1,2,3,4,5). From the clinical statistics on methemoglobinemia it has been deduced that sulfanilamide is partially converted by the body into some active agent which can function as an oxidant (5).
…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Inasmuch as methemoglobin is formed from hemoglobin only by oxidizing agents (e.g., ferricyanide), the uniform occurrence of some methemoglobin in the red cells of all patients treated with the sulfonamide drugs (3,14) is excellent evidence that the body produces oxidizing agents from these drugs (15). Furthermore, one such oxidant, hydroxylaminobenzene sulfonamide, unlike ferricyanide, can penetrate the erythrocyte membrane and is detectable in the urine during sulfanilamnide therapy (16).…”
Section: Methodsmentioning
confidence: 99%
“…This is not the case. Most patients receiving huge doses over long periods of time with correspondingly large amounts of methemoglobin in their cells (up to 40 per cent in man (14), 75 per cent in monkeys (17)), do not develop hemolysis. On the other hand, when hemolytic anemia occurs, it appears early-within 2 to 5 days from the start of administration, and after only moderate doses of the drug (only 12 grams in one of the present cases).…”
Section: Methodsmentioning
confidence: 99%